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Background: Relapsed T-lineage acute lymphoblastic leukemia (T-ALL) has been an incurable disease. Recent
reports showed that an L-arginine depleting enzyme, pegylated arginase (BCT-100) may be effective against T-ALL
cells. On the other hand, studies including ours had shown the symbiosis of ALL blasts and human mesenchymal
stromal cells (hMSCs) in bone marrow microenvironment during L-asparaginase treatment. As L-asparaginase and
BCT-100 both act by depleting lymphoid cells of specific amino acid, we hypothesized that hMSCs may also protect
T-ALL blasts from BCT-100 treatment in co-culture and such protection may be abrogated by pre-treating hMSCs
with vincristine (VCR).
Methods: XTT assay was used to test sensitivities of T-ALL cell lines and hMSCs to BCT-100. Apoptosis of T-ALL cell
lines with or without BCT-100 treatment were tested by annexin V / propidium iodide (AV/PI) assay using flow
cytometer. Western blotting was performed to analyze the expression of ornithine transcarbamylase (OTC), an
enzyme involved in L-arginine metabolism which may account for BCT-100 resistance.
Results: hMSCs were resistant to BCT-100 while CCRF-CEM, Jurkat and MOLT-4 were very sensitive to it. hMSCs
could protect all the three cell lines from BCT-100 treatment in transwell co-culture. All the 3 T-ALL cell lines were
also found to be rescued by an L-arginine precursor citrulline, while the breakdown product of BCT-100, ornithine
only had limited salvaging effect on CCRF-CEM but not Jurkat and MOLT-4. Both hMSCs and 3 T-ALL cell lines
express citrulline synthesis enzyme, ornithine transcarbamylase (OTC) at basal level while only hMSCs could
express OTC at relatively higher level under BCT-100 treatment. Treating hMSCs with vincristine before co-culturing
with T-ALL could resume the cytotoxicity of BCT-100 to CCRF-CEM and MOLT-4 cells.
Conclusions: Our results suggest a possible strategy to overcome resistance to BCT-100 from cancer
microenvironments by suppressing hMSCs either in marrow or in the perivascular niche using vincristine.
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Stromal suppressionBackground
Acute lymphoblastic leukemia (ALL) is the commonest
form of pediatric malignancies which originates from
lymphoid precursors [1]. ALL can be divided into 2 sub-
types, B-lineage ALL (B-ALL) accounts for 85% of all
cases and the remaining 15% are T-lineage ALL (T-ALL)
[2]. With the advances in anti-cancer drugs development
and treatment regimen design, the long term event free* Correspondence: gcfchan@hku.hk
Department of Paediatrics & Adolescent Medicine, Li Ka Shing Faculty of
Medicine, The University of Hong Kong, Hong Kong, SAR, China
© 2013 Kwong-Lam and Chi-Fung; licensee Bi
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumsurvival of childhood ALL can be up to 85% these days
[3]. However, T-ALL is known to have less favorable
prognosis and relapse is more common probably due to
emergence of chemo-resistance [4]. For patients with re-
lapsed T-ALL, there is still no effective curative strategy
up to the moment.
L-asparaginase is a commonly used chemotherapeutic agent
in both B-ALL and T-ALL. Its main mechanism is by deple-
tion of L-asparagine, a non-essential amino acid. Leukemic
blasts lack L-asparaginase resulting in chemoresistance. It
has been shown that mesenchymal stromal cells (MSCs)oMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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blasts in bone marrow microenvironment by secreting as-
paragine [5]. On the other hand, MSCs have a peculiar
chemo-sensitivity pattern. MSCs are resistant to most of
the commonly used chemotherapeutic agents for leukemia,
but remain sensitive to anti-microtubule agents such as
paclitaxel and vincristine (VCR) [6]. In almost all currently
adopted protocols for childhood ALL, it is recommended
to administer VCR 1 or 2 days prior to L-asparaginase ad-
ministration [7]. Traditional view was that such practice
can suppress the allergic reaction to asparaginase. However,
our previous work provided a new rationale on this treat-
ment design. We showed that vincristine can temporarily
disrupt the stromal support to leukemic blasts and retain
the L-asparagine depleted microenvironment [8]. However,
the high intrinsic asparaginase resistance in T-ALL blasts
implies B-ALL chemotherapy regimens may not be as ef-
fective as in T-ALL patients [5,9]. Drugs with higher effi-
cacy against T-ALL are urgently needed.
Recent reports showed that another amino acid deplet-
ing agent, pegylated arginase I (BCT-100), is effective
against T-ALL both in vitro and in vivo [10,11]. BCT-100
is purified from B. subtilis followed by pegylation for
prolonging its bio-activity [12]. Arginase breaks down
L-arginine into ornithine and urea. This has been pro-
posed as a novel anti-cancer agent because many types
of cancer cells cannot synthesize L-arginine [12,13].
However, cells may potentially be resistant to BCT-100
if they express ornithine transcarbamylase (OTC) or
they are able to utilize citrulline under an L-arginine
starvation setting [14]. As the nutrient-depleting mechan-
ism of BCT-100 is similar to L-asparaginase, we suspect
that T-ALL blasts may acquire chemo-resistance to BCT-
100 in a manner similar to that of L-asparaginase re-
sistance induced by hMSCs to B-ALL. Therefore we
hypothesized that: 1) hMSCs may protect T-ALL blasts
from BCT-100 induced cytotoxicity by providing soluble
factors involved in L-arginine metabolism; and 2) BCT-100
resistance induced by hMSCs may be overcome by pre-
treating MSCs with vincristine.
Results and discussion
T-ALL cell lines were BCT-100 sensitive while hMSCs were
BCT-100 resistant
The cell viabilities under BCT-100 treatment were assessed.
The tested samples included 3 T-ALL cell lines, CCRF-
CEM, Jurkat and MOLT-4; human telomerase reverse tran-
scriptase immortalized MSCs (hTertMSCs); and hMSCs
from healthy donors. The dosages of BCT-100 ranged from
0.3125 U/ml to 10 U/ml. All three T-ALL cell lines were
sensitive to BCT-100 in a dose-dependent manner. The cell
viability of the three T-ALL cell lines dropped below IC50
even with the lowest dose of 0.3125U/ml (p < 0.005 for all
T-ALL cell lines used) (Figure 1a, b and c). On the otherhand, the cell viabilities of hTertMSCs and hMSCs
remained around 80% even as the BCT-100 dose was
stepped up to 10 U/ml (p < 0.005) (Figure 1d and e). It is
consistent with the previous report that BCT-100 could
suppress cell proliferation of both B-ALL and T-ALL [10].
We showed that hMSCs were resistant to BCT-100 and
such differential cytotoxicity of BCT-100 to T-ALL blasts
and hMSCs might imply a possible symbiosis between
T-ALL and hMSCs during arginine starvation stress,
similar to the B-ALL blasts/hMSCs symbiosis during
asparagine depletion [5].
hMSCs partly protected T-ALL cells from BCT-100 induced
apoptosis
hMSCs is an important component of bone marrow
microenvironment and perivascular niche. It was shown
to be resistant to most chemotherapeutic agents [6].
With its intrinsic resistance properties, hMSCs also
serve as a supporting niche to cancer cells against che-
motherapeutic damage. This protective effect can be
found in both solid tumors and leukemia [5,15,16]. In
relapsed T-ALL, T-ALL blasts can metastasize to all
compartments of the body with grave prognosis. The
MSCs residing in the bone marrow microenvironments
may provide protection to T-ALL blasts against chemo-
therapy induced cell death. Such concept is supported
by a recent in vivo study of BCT-100 in mice [11]. Fur-
thermore, hMSCs can also be found in adipose tissue
and around blood vessels as pericytes [17]. Therefore,
T-ALL blasts inside the patients’ body may very likely
interact with hMSCs not only in the bone marrow micro-
environment, but also along the blood vessels. For ensur-
ing efficacy of BCT-100 against T-ALL, it is important to
test whether hMSCs and T-ALL cells have symbiotic rela-
tionship during BCT-100 treatment. The transwell co-
culture system was used to test whether soluble factors in
co-culture contributed to protection against BCT-100 in
T-ALL blasts. Under ordinary culture conditions, hMSCs
did not provide any significant enhancement in survival to
T-ALL blasts (Figure 2a). However, hMSCs could protect
all 3 T-ALL cell lines used, CCRF-CEM, Jurkat and
MOLT-4, against BCT-100 induced apoptosis. Percentage
of apoptosis was reduced by as high as 26% in average as
shown in CCRF-CEM/hMSCs transwell co-culture, com-
pared to CCRF-CEM alone, p < 0.01 (Figure 2b). For
Jurkat/hMSCs and MOLT-4/hMSCs transwell co-culture,
the average percentages of apoptosis were reduced by
about 20%, p < 0.05 and 15%, p < 0.05 compared to
Jurkat and MOLT-4 alone. (Figure 2b) Here we dem-
onstrated that involvement of stroma secreted soluble
factors would be sufficient in protecting T-ALL blasts
against BCT-100.
We first hypothesized the involvement of cytokines in
the hMSCs/T-ALL blasts interaction during BCT-100
Figure 1 The cytotoxic assessment of BCT-100 on T-ALL blasts, hTertMSCs and hMSCs showed a dose-dependent response for T-ALL
blasts but not MSCs. (a) CCRF-CEM, (b) Jurkat, (c) MOLT-4, (d) hTertMSCs and (e) hMSCs were treated with PBS (control) or different doses of
BCT-100 (0.15625, 0.3125, 0.625, 1.25, 2.5 and 5 U/ml) for 48 hours, then subjected to XTT analysis. Values of cells viabilities were the representative
results derived from 3 consistent experiments with error bars showing standard deviation. ***: p < 0.005 compared to control (0 U/ml).
Kwong-Lam and Chi-Fung Experimental Hematology & Oncology 2013, 2:11 Page 3 of 9
http://www.ehoonline.org/content/2/1/11treatment. A previous report showed that IL-8 was up-
regulated in T-ALL cells refractory to chemotherapy
[18]. IL-8 is known to be secreted by both hMSCs and
T-ALL cells [19,20]. However, other reports reported
that CCRF-CEM, Jurkat, MOLT-4 and primary T-ALL
cells do not express IL-8 receptors CXCR1 and CXCR2
[19,21]. It implies that IL-8 works on the cancer micro-
environment mainly by enhancing angiogenesis and im-
mune cell migration [19]. Therefore IL-8 may not be an
important factor in stromal protection to T-ALL blasts
against BCT-100. Therefore, we then investigated whether
the possible soluble factors involved are chemicals mainly
involve in arginine metabolism.
Ornithine and citrulline could partly rescue T-ALL cells
BCT-100 works by breaking down L-arginine into orni-
thine and urea. In urea cycle, ornithine can combine withcarbamoyl phosphate to form citrulline. Citrulline can
then be recycled to L-arginine (Figure 3a). Carbamoyl
phosphate and citrulline are both present in blood. There-
fore if any cancer cells can utilize ornithine or citrulline
during arginine starvation, they may be resistant to the de-
pletion effect of BCT-100 by recycling these intermediate
metabolites. In order to determine whether these three
T-ALL cell lines can utilize this recycling pathway, the
rescuing effect of either ornithine or citrulline on the
T-ALL cell lines from BCT-100 induced cell death was
investigated. We found that ornithine could reduce the
percentage of cell death by about 10% only in CCRF-CEM
(p < 0.05), but not in Jurkat and MOLT-4 during BCT-100
treatment (Figure 3b). However, the rescue effect for
CCRF-CEM was not dose dependent. These results imply
that the direct break-down product of L-arginine, orni-
thine, could not be utilized by T-ALL cells. Although the
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Figure 2 Apoptosis of T-ALL cell line treated with or without BCT-100 under stromal support/culture alone. (a) CCRF-CEM, Jurkat or
MOLT-4 cell lines were cultured for 36 hours with or without hMSCs or hTertMSCs transwell co-culture. Annexin V / FITC Propidium iodide (AV/PI)
assay was performed to test the percentage of apoptosis. (b) CCRF-CEM, Jurkat or MOLT-4 cell lines were treated with 1 U/ml BCT-100 for 36
hours with or without transwell co-culture with hMSCs or hTertMSCs. AV/PI assay was performed to test the percentage of apoptosis. The
average apoptotic percentages of the 3 T-ALL cell lines were significantly increased but such effect was partly attenuated by co-culturing with
hTertMSCs and hMSCs from different donors. All experiments were done in triplicate and error bars showed respective standard deviation.
*: p < 0.05 between T-ALL / hMSCs co-culture and T-ALL culture alone. **: p < 0.01 between T-ALL / hMSCs co-culture and T-ALL culture alone.
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ornithine to overcome the depletion induced by BCT-100,
it is important to determine whether other L-arginine pre-
cursors such as citrulline may be able to rescue the blasts.
Even citrulline is not generated directly from the catabolic
effect of BCT-100, it may be available from other extrinsic
sources such as the hMSCs. We found that 0.1mM citrul-
line could significantly reduce cell death in the CCRF-
CEM, Jukrat and MOLT-4 by 12.1%, p < 0.01, 42.7%,
p < 0.005 and 35%, p < 0.005, respectively (Figure 3c).
The result may contradict a previous report that citrulline
could not significantly rescue CCRF-CEM from BCT-100
induced cell death [10]. While in another report, Jurkat
cell line could utilize citrulline but not arginino-succinate
for growth in the absence of L-arginine in vitro [14]. The
difference may be related to the dose of citrulline used.
The citrulline dose that we used (0.1 mM) was 2.5 fold
higher than the average plasma citrulline level in healthy
subjects (below 40 μM) [22]. High citrulline level may
occur in tissues having high ornithine transcarbamoylase
(OTC) activity during BCT-100 treatment. T-ALL cells
residing in these sites may acquire resistance to BCT-100
by utilizing citrulline to replenish the depleted arginine.
As hMSCs exist not only in bone marrow stroma but also
as pericytes around blood vessels, it is important to test
whether hMSCs protect T-ALL cells against BCT-100 in-
duced cell death partly by their up-regulation of OTC ex-
pression during BCT-100 treatment.
hMSCs protected T-ALL cell lines against BCT-100 induced
cytotoxicity possibly in part by their sustained OTC
expression
Ornithine transcarbamoylase is an enzyme important in
urea cycle for arginine synthesis, and it may protect cellsagainst BCT-100 induced arginine depletion. It is known to
be highly expressed in liver and gut tissues [12]. However,
OTC expression in other tissues has not been documented.
In Figure 1, hMSCs were shown to be BCT-100 resistant
and the 3 T-ALL cell lines tested were BCT-100 sensitive.
It is important to know whether such phenomenon is due
to differential expression of OTC in hMSCs and T-ALL
cells during BCT-100 treatment. By Western blotting we
showed that all hTertMSCs, two hMSCs from healthy do-
nors, CCRF-CEM, Jurkat and MOLT-4 expressed OTC
(Figure 4a). This is intriguing as OTC expressing cells are
expected to be resistant against L-arginine depletion, which
is in contrast to our findings showing the susceptibility of
T-ALL cell lines to BCT-100 induced cell death. Further-
more, OTC expressing T-ALL cells lines were expected to
have improved survival with ornithine supplement during
BCT-100 treatment. Unexpectedly, ornithine failed to res-
cue Jurkat and MOLT-4 against BCT-100 treatment.
Therefore we tested the OTC expression of hMSCs
and T-ALL cells during BCT-100 treatment. By West-
ern blotting, we showed that the OTC expression of
hMSCs and the 3 T-ALL cells’ decreased significantly
after BCT-100 treatment. But such down-regulation
occurred in different degrees, the OTC expression in
hMSCs but not T-ALL cells remains at a relatively high
level (Figure 4b, c, d & e). The suppression of OTC ac-
tivity among T-ALL cells may hinder the conversion of
ornithine to citrulline and eventually leading to the
failure in replenishing L-arginine. It is possible that hMSCs
protect themselves and also the adjacent T-ALL cells by
their sustained OTC expression during BCT-100 treatment
by secreting citrulline. Therefore T-ALL cells may utilize
extrinsic citrulline to survive despite L-arginine deprivation.
In order to disrupt the symbiotic relationship between
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Figure 3 Apoptosis induced by BCT-100-treated T-ALL cells could be rescue by citrulline but not ornithine. (a) The relationship between
BCT-100 action and L-arginine metabolism. (b) Apoptosis of BCT-100-treated T-ALL cell lines could not be rescued by ornithine in 2 of the 3
T-ALL cell lines tested. CCRF-CEM, Jurkat or MOLT-4 cell lines were treated with BCT-100 with or without ornithine (doses ranged from 1 mM to
10 mM) for 36 hours. Annexin V / FITC Propidium iodide (AV/PI) assay was performed to test the percentage of apoptosis. Only CEM showed a
modest reduction of BCT-100 induced apoptosis after the addition of ornithine. The average apoptotic percentages of the 3 T-ALL cell lines were
derived from 3 independent experiments for each T-ALL cell line with error bars showing standard deviation. **: p < 0.01 between BCT-100 only
and BCT-100 + different doses of ornithine. ***: p < 0.005 between BCT-100 only and BCT-100 + different doses of ornithine. (c) Apoptosis of BCT-
100-treated T-ALL cell lines could be rescued by citrulline. CCRF-CEM, Jurkat or MOLT-4 were treated with BCT-100 with or without 0.1 mM
citrulline for 36 hours. Annexin V / FITC Propidium iodide (AV/PI) assay was performed to test the percentage of apoptosis. All 3 T-ALL cells
showed a reduction in apoptosis after the addition of citrulline. The average apoptotic percentages of the 3 T-ALL cell lines were obtained after
triplicated experiment of the corresponding T-ALL cell line with error bars showing standard deviation. *: p < 0.05 between BCT-100 only and
BCT-100 + 0.1 mM citrulline. ***: p < 0.005 between BCT-100 only and BCT-100 + 0.1 mM citrulline.
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http://www.ehoonline.org/content/2/1/11hMSCs and T-ALL cells during BCT-100 treatment, we
tried to test whether we could suppress hMSCs support to
T-ALL cells by inhibiting the function of hMSCs with VCR,
an anti-microtubule agent that have been shown to sup-
press the proliferation and function of hMSCs. In addition,
vincristine is also a known potent anti-angiogenesis agent
that can effectively inhibit blood vessel formation including
those in the cancer microenvironment.
Vincristine pre-treatment on hMSCs could potentially
override the protective effect of hMSCs on T-ALL cells
during BCT-100 treatment
hMSCs are resistant against most of the commonly used
chemotherapeutic agents in vitro, however, they remain
sensitive to drugs that disrupt micro-tubules function
such as paclitaxel and VCR [6]. There were also reports
showing that intensive combinational chemotherapiescause reduction in number of hMSCs in the form of col-
ony forming unit fibroblasts (CFU-F) isolated from bone
marrow aspirates, the dose and synergistic effects of
various chemotherapeutic agents may account for the
differences [23,24]. Therefore, both anti-microtubules
agents and intensive chemotherapy may reduce hMSCs
viability, and hence the stromal support to tumor cells
in bone marrow micro-environment. Since VCR is a
commonly used chemotherapeutic agent and its sup-
pressive effect on MSCs is partly reversible, we selected
VCR as our hMSCs suppressor. We hypothesized that
by pre-treating hMSCs with VCR, the hMSCs protection
to T-ALL blasts against BCT-100 induced cytotoxicity
may be suppressed. By AV/PI assay using flow cytometry
we showed that pre-treating hMSCs or hTertMSCs with
VCR did not increase the percentage of T-ALL blasts
apoptosis in all the three T-ALL cell lines (Figure 5a).
Figure 4 Ornithine transcarbamylase (OTC) is expressed in both hMSCs and T-ALL cells and BCT-10 treatment could suppress OTC
expression significant in T-ALL cells but only modestly on MSCs. (a) Basal expression of OTC in hTertMSCs, hMSCs from 2 healthy donors,
CCRF-CEM, Jurkat and MOLT-4. Cells were harvested and respective proteins were extracted from the corresponding cell lines. SDS-PAGE was
performed to separate the proteins. OTC and β-actin (internal control) expression were probed by the corresponding antibodies and then
visualized by enzyme coupled luminescence (ECL). (b) Expression of OTC in hMSCs after BCT-100 treatment. hTertMSCs or hMSCs from a healthy
donor were cultured in different doses of BCT-100 (0 U/ml, 0.5 U/ml, 1 U/ml and 2 U/ml) for 36 hours and protein was extracted from the cell
culture. SDS-PAGE followed by Western blotting was performed. The expression of OTC and β-actin (internal control) of hTertMSCs is presented in
the figure. (c), (d) and (e) Expression of OTC in CCRF-CEM, Jurkat or MOLT-4 after BCT-100 treatment respectively. CCRF-CEM, Jurkat and MOLT-4
were cultured in different doses of BCT-100 (0 U/ml, 0.5 U/ml, 1 U/ml and 2 U/ml) for 36 hours and protein was extracted. SDS-PAGE followed by
Western blotting was performed. The expression of OTC and β-actin (internal control) of CCRF-CEM, Jurkat or MOLT-4 is presented in the figures.
The most representative results are presented.
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http://www.ehoonline.org/content/2/1/11This excluded the possibility that residual VCR from
hMSCs culture medium might cause significant damage
to T-ALL blasts. Then we showed that VCR pre-
treatment on hMSCs could partly eliminate the protect-
ive effect of hMSCs to CCRF-CEM and MOLT-4 cells in
co-culture, by 15%, p < 0.05 and 11%, p < 0.05, respect-
ively, compared to co-culture without vincristine pre-
treated hMSCs (Figure 5b). But such maneuver does not
benefit Jurkat co-cultured with hMSCs. This may be due
to a cell-line-specific phenomenon. The dependence of
Jurkat cells to the stromal support during BCT-100
treatment may be low at base line, such that minimal
level of arginine or citrulline secreted from the hMSCs
may be adequate for rescue. What really account for the
difference remains to be investigated further. In sum-
mary, the response of the other 2 T-ALLs is in concord-
ance to our previous report that VCR can suppress
stromal support to B-ALL blasts against L-asparaginase
cytotoxicity [8]. Such approach may help to restore the
sensitivity of most T-ALL blasts to BCT-100 cytotox-
icity. Our experiment results imply that vincristine may
synergize with BCT-100 in vivo; this requires further
verification by in vivo study.Conclusions
Differential toxicity of BCT-100 to T-ALL blasts and
hMSCs was observed. BCT-100 induced significant cyto-
toxicity to 3 T-ALL cell lines including CCRF-CEM,
Jurkat and MOLT-4 but not hMSCs. With such differen-
tial response between T-ALL cells and hMSCs as basis,
the interaction of hMSCs and T-ALL blasts during BCT-
100 treatment was further investigated. hMSCs could
partly rescue all 3 T-ALL cell lines from BCT-100 induced
toxicity. While testing for the involvement of L-arginine
metabolic pathway substrates in the rescue mechanism, all
the 3 T-ALL cell lines tested could utilize citrulline for en-
hancing survival during BCT-100-induced L-arginine
deprivation. On the other hand, only CCRF-CEM could
marginally utilize ornithine for survival during BCT-100
treatment. hMSCs and all 3 T-ALL cell lines expressed
OTC, which means both hMSCs and T-ALL blasts should
be capable of converting ornithine into citrulline and
eventually recycling L-arginine even under BCT-100 treat-
ment. However, the expression of OTC could also be
suppressed in both hMSCs and T-ALL cell lines during
BCT-100 treatment. Despite the decrease in OTC expres-
sion, expression in hMSCs remained relatively higher than
ba
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Figure 5 Apoptosis of T-ALL cell lines treated with BCT-100 under stromal support/ VCR pre-treated stromal support. The protective
effect of hMSCs on T-ALLs during BCT-100 treatment could be abolished by pre-treating hMSCs with vincristine. (a) Baseline Apoptosis of T-ALL
cell lines was not affected by VCR pre-treatment on hMSCs. CCRF-CEM, Jurkat or MOLT-4 cells were cultured for 36 hours with hMSCs or
hTertMSCs transwell co-culture. MSCs were with or without vincristine pre-treatment for 3 days. Annexin V / FITC Propidium iodide (AV/PI) assay
was performed to test the percentage of apoptosis. (b) VCR pre-treatment on hMSCs could partly re-establish the chemosensitivity of T-ALL cells
to BCT-100 as in those without stromal support. hMSCs or hTertMSCs were pre-treated with or without VCR for 3 days, after washing the cells
extensively with PBS, CCRF-CEM, Jurkat or MOLT-4 were co-cultured with the pre-treated hMSCs or hTertMSCs. 1 U/ml BCT-100 was used to treat
the co-cultures for 36 hours. Then the T-ALL cells were harvested and AV/PI assay was performed to test the percentage of apoptosis. The
average apoptotic percentages of the 3 T-ALL cell lines were obtained under transwell co-culture with hMSCs from different donor including
hTertMSCs. All experiments were done in triplicate with error bars showing standard deviation. *: p < 0.05 between T-ALL / hMSCs co-culture and
T-ALL/ VCR pre-treated hMSCs co-culture.
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expression between hMSCs and T-ALL cells during BCT-
100 treatment suggested that hMSCs could potentially
protect T-ALL cells from BCT-100 treatment by their
sustained OTC expression. In order to suppress the stro-
mal protection to T-ALL blasts, hMSCs could be pre-
treated with vincristine (VCR). The protective effect of
hMSCs to 2 of the 3 T-ALL cell lines against BCT-100
were abolished with this approach. This suggests a possible
synergy between VCR and BCT-100 in treating T-ALL in
the cancer microenvironment, similar to the synergy of
VCR and L-asparaginase in ALL chemotherapy protocol.
Further investigation using animal studies may help to im-
prove the efficacy of BCT-100, especially when in combin-
ation with VCR.
Material & methods
Cell culture
Bone marrow mononuclear cells from healthy young
adults’ bone marrow transplantation donor were
obtained with written informed consent under approval
of Institutional Review Board (The Hong Kong Univer-
sity and Hong Kong West Cluster Hospitals). The bone
marrow-derived human MSCs were expanded and char-
acterized in vitro according to our previous published
method [6]. The human telomerase reverse transcriptase
immortalized MSCs (hTertMSCs) was a gift from Prof.
D. Campana (St Jude Children's Research Hospital,
Memphis, Tennessee) [25]. hTertMSCs or hMSCs were
cultured in low-glucose Dulbeco's Minimal EssentialMedium (DMEM-LG) supplemented with 10% fetal bo-
vine serum (FBS), 1% penicillin/ streptomycin (P/S), and
1% L-glutamine. CCRF-CEM, Jurkat and MOLT-4 are
T cell lineage ALL cell lines purchased from American
Type Culture Collection (ATCC). The 3 T-ALL cell
lines were cultured in RPMI 1640 supplemented with
10% FBS, 1% HEPES, 1% Penicillin / Streptomycin.Antibodies and chemicals
BCT-100 was provided by Dr Cheng NM, Paul of Bio-
Cancer Treatment Ltd. Vincristine was purchased from
Eli Lily (Eli Lily and Company Incorporated, UK). Mouse
Anti-human OTC antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-human
β-actin antibody was purchased from Cell Signaling Tech-
nology (Danvers, MA). L-citrulline and L-ornithine were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).Transwell co-culture of MSCs and T-ALL cell lines
hTertMSCs or hMSCs were seeded at the density of 1 × 104
cells/well onto 12-well plates. They were then treated with
or without vincristine sulfate (VCR, Eli Lily and Company
Incorporated, UK) as previously described [8]. Both MSCs
were washed with phosphate buffered saline and then incu-
bated with RPMI 1640 medium supplemented with 10%
FBS, 1% HEPES, 1% penicillin/streptomycin and 1%
L-glutamine. ALL blasts (1 × 105) (CCRF-CEM, Jurkat
or MOL-4) were seeded onto the transwell insert of
the 12-well plates seeded with the previously seeded
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with or without 1 U/mL BCT-100 for 36 hours.
Cell viability
Cells were plated at 104 per well in 96 well plate with increas-
ing concentration of BCT-100 (0.3125 U/ml, 0.625 U/ml,
1.25 U/ml, 2.5 U/ml, 5 U/ml and 10 U/ml) for 48 hours at
37°C. Cell viability was determined by a colorimetric method
using XTT cell proliferation assay kit according to manufac-
turer’s instructions (Roche Diagnostics, Switzerland).
Protein extraction and Western blot analysis
Protein extraction and Western blot analysis were carried
out as follow. After treatment, cells were washed with
phosphate buffered saline, and then resuspended in lysis
buffer (phosphate-buffered saline containing 1% Nonidet
P-40, 0.5% sodium deoxycholate and 0.1% SDS) containing
the protease inhibitors (100 μg/ml phenylmethylsulfonyl
fluoride and 1 mM sodium fluoride). The lysate was incu-
bated on ice for 20 min, and then centrifuged at 13,200
rpm for 20 min at 4°C. Protein concentration was deter-
mined using the Bio-Rad protein assay. Whole cell lysate
containing 15 μg of protein from each sample were used in
immunoblotting, and subsequently the gels were electro-
blotted onto PVDF membranes (Immobilon-P, Millipore).
Antibodies purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) and Cell Signaling Co. (Danvers, MA)
were used to detect the proteins of interest. The horserad-
ish peroxidase conjugated antibodies against mouse and
rabbit IgG were used as secondary antibodies (Sigma-
Aldrich, St. Louis, MO). The secondary antibody binding
was detected by ECL Western detection blotting reagents
(GE Healthcare, USA) and detected by Fuji Medical X-Ray
Film (Fuji, Japan).
Apoptosis analysis
AV/PI (Annexin V-FITC Kit, Becton, Dickinson and
Company, NJ) was used to assess the extent of apop-
tosis of T-ALL cells after exposure to arginase treat-
ment. T-ALL blasts in transwell co-culture were harvested,
washed and then re-suspended in 1X AV binding buffer
provided by the commercial kit. The cells were labeled
with AV-FITC and propidium iodide (PI) following the
manufacturer's instruction and analyzed by flow cy-
tometry. Flow cytometric analysis was performed with
a BD LSR II (BD Biosciences, San Jose, CA). Ten thou-
sand events per sample were collected into list mode
files and analyzed by FlowJo.
Statistical analysis
Experiments were performed for 3 times with consistent
results. Comparisons between mean values were made
using two way's analysis of variance (ANOVA) or pairedStudent t test (one-tailed). The differences were consid-
ered statistically significant when p < 0.05.
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